A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion

Indranil Chakravorty, Kamaljit Chahal, Gillian Austin, Indranil Chakravorty, Kamaljit Chahal, Gillian Austin

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) patients with mucus hypersecretion tend to demonstrate increased frequency of infective exacerbations and a steeper slope of decline in lung function. Enhanced mucociliary clearance with high-frequency chest wall oscillation (HFCWO) devices previously used in cystic fibrosis and bronchiectasis patients may offer the opportunity for community-based, self-managed therapy to improve quality of life and lung function.

Study design and methods: A randomized controlled crossover pilot study of HFCWO compared with conventional treatment was conducted in 22 patients with moderate to severe COPD and mucus hypersecretion. Patients spent 4 weeks using an HFCWO (SmartVest(®)) device and 4 weeks in a conventional phase with a 2-week washout. Eleven patients started with HFCWO and changed to conventional treatment, whereas the other eleven patients started conventional treatment and crossed over to HFCWO.

Results: The patients were elderly with a mean age of 71 (standard deviation [SD] 10) years and were at the upper end of the normal range of body mass index (25 [SD 4.2] kg/m(2)). The majority of patients had moderate to severe COPD with a mean percentage predicted forced expiratory volume in 1 second of 41 (SD 15.6) and percentage predicted forced vital capacity of 73 (SD 17.7). Baseline sputum production was negatively correlated to lung function and positively to St George's Respiratory Questionnaire. Symptom scores and St George's Respiratory Questionnaire symptom dimension improved significantly (-8, P < 0.05). Sputum production showed a declining trend in the HFCWO phase, although not reaching statistical significance. The HFCWO device was well tolerated with good reported compliance.

Conclusion: This pilot study demonstrated that patients with advanced COPD and mucus hypersecretion at increased risk of declining lung function tolerated the HFCWO treatment well, leading to improvement in quality of life and reduced symptoms.

Trial registration: ClinicalTrials.gov NCT00863616.

Keywords: bronchiectasis; sputum volume; symptom scopes.

Figures

Figure 1
Figure 1
Scatter plot demonstrating the relationship between sputum volume (mL) and lung function (forced expiratory volume in 1 second percentage predicted [FEV1PRED]).
Figure 2
Figure 2
Boxplots representing median and interquartile range change in lung function (predicted forced expiratory volume in 1 second [FEV1] percent predicted and forced vital capacity [FVC] percent predicted) from baseline after intervention in high-frequency chest wall oscillation (phase 1) and conventional arm (phase 2).
Figure 3
Figure 3
Boxplots demonstrating the St George’s Respiratory Questionnaire domain and total scores before and after intervention in both arms of the study (high-frequency chest wall oscillation B to v1 and conventional phase v2 to v3).

References

    1. Mapel D, Chen JC, George D, Halbert RJ. The cost of chronic obstructive pulmonary disease and its effects on managed care. Manag Care Interface. 2004;17:61–66.
    1. Miller RM, George D, Halbert RJ. Improving the management of chronic obstructive pulmonary disease. J Healthc Qual. 2005;27:42–47.
    1. Sin DD, Man SFP. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:624–629.
    1. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med. 2006;119(10 suppl 1):38–45.
    1. Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression. Proc Am Thorac Soc. 2007;4:586–590.
    1. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396–401.
    1. Makris D, Moschandreas J, Damianaki A, et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101:1305–1312.
    1. Pryor JA. Physiotherapy for airway clearance in adults. Eur Respir J. 1999;14:1418–1424.
    1. Wolkove N, Baltzan MA, Jr, Kamel H, Rotaple M. A randomized trial to evaluate the sustained efficacy of a mucus clearance device in ambulatory patients with chronic obstructive pulmonary disease. Can Respir J. 2004;11:567–572.
    1. Livraghi A, Randell SH. Cystic fibrosis and other respiratory diseases of impaired mucus clearance. Toxicol Pathol. 2007;35:116–129.
    1. Kendrick AH. Airway clearance techniques in cystic fibrosis. Eur Respir J. 2006;27:1082–1083.
    1. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc Am Thorac Soc. 2004;1:42–46.
    1. King M, Phillips DM, Zidulka A, Chang HK. Tracheal mucus clearance in high-frequency oscillation. II: chest wall versus mouth oscillation. Am Rev Respir Dis. 1984;130:703–706.
    1. van der Schanns CP. Conventional chest physical therapy for obstructive lung disease. Respir Care. 2007;52:1198–1206.
    1. Button B, Boucher RC. Role of mechanical stress in regulating airway surface hydration and mucus clearance rates. Respir Physiol Neurobiol. 2008;163:189–201.
    1. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–1535.
    1. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364:709–721.
    1. Rodriguez-Roisin R. The airway pathophysiology of COPD: implications for treatment. COPD. 2005;2:253–262.
    1. Kobylianskii VI, Gamal EA. Mucoactive therapy and new aspects of the pathogenesis of chronic obstructive pulmonary disease. Klin Med (Mosk) 2006;84:15–24.
    1. Bhowmik A, Chahal K, Austin G, Chakravorty I. Improving mucociliary clearance in chronic obstructive pulmonary disease. Respir Med. 2009;103:496–502.
    1. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25–31. discussion 33–37.
    1. Kempainen RR, Williams CB, Hazelwood AR, et al. Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis. Chest. 2007;132:1227–1232.
    1. Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology. 2006;67:991–997.
    1. Piquet J, Brochard L, Isabey D, et al. High frequency chest wall oscillation in patients with chronic air-flow obstruction. Am Rev Respir Dis. 1987;136:1355–1359.
    1. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48:1204–1213.
    1. Their SL, Yu-Isenberg KS, Leas BF, et al. In chronic disease, nationwide data show poor adherence by patients to medication and by physicians to guidelines. Manag Care. 2008;17:48–52.
    1. Gillisen A. Patients’ adherence in asthma. J Physiol Pharmacol. 2007;58(Suppl 5):205–222.
    1. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005;2:75–79.
    1. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565–1572.
    1. Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med. 2008;102:367–376.
    1. Patterson JE, Hewitt O, Kent L, et al. Acapella versus ‘usual airway clearance’ during acute exacerbation in bronchiectasis: a randomized crossover trial. Chron Respir Dis. 2007;4:67–74.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe